Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Chemed (CHE)

Chemed Q4 revenue rises 7.2% to $585.9 million; 2024 EPS guidance $23.30-$23.70

Positive Impact 3 of 5 earnings Written later

Chemed reported fourth-quarter 2023 revenue of $585.9 million, up 7.2%, with GAAP diluted EPS of $5.90, up 42.9%, and adjusted diluted EPS of $6.60, up 35.0%. The company gave 2024 adjusted diluted EPS guidance of $23.30 to $23.70, compared with $20.30 in 2023, while Roto-Rooter revenue fell 1.1% in the quarter.

Key points

  • Q4 2023 revenue rose 7.2% to $585.9 million; GAAP diluted EPS was $5.90 and adjusted diluted EPS was $6.60
  • VITAS net patient revenue rose 13.6% to $350.0 million; Roto-Rooter revenue fell 1.1% to $235.9 million
  • 2024 guidance: adjusted diluted EPS of $23.30 to $23.70 versus $20.30 adjusted EPS in 2023
  • As of December 31, 2023, cash and cash equivalents were $264.0 million with no current or long-term debt

The filing

CompanyChemed (CHE)
Form8-K, current report
Filed with the SECFeb 27, 2024, 4:33 PM ET
Accession number0001562762-24-000036

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.